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QALYs gained, utility scores for responders and nonresponders
were derived from UK expert estimates and parent-proxy-
ratings. Incremental cost-effectiveness ratios (ICERs) were calcu-
lated including a range of scenarios for maintenance treatment
over an additional 12 months, and were subjected to multiple
sensitivity analyses. RESULTS: Eight-week remission rates were
4% (MPH b.i.d.), 23% (MPH-IR t.i.d.), and 47% (MPH-
OROS). For cost per response achieved, ICERs were €388 for
MPH-OROS versus MPH-IR t.i.d. and €206 versus MPH-IR
b.i.d.; ICERs for maintenance of response over 14 (2 + 12)
months were €2,773 for MPH-OROS versus MPH-IR t.i.d. and
€2,224 versus MPH-IR b.i.d., assuming that nonresponders dis-
continue drug treatment. Cost-per-QALY-gained for MPH-
OROS versus MPH-IR t.i.d. was between €16,500 and €44,000,
or €11,200 to €26,200 after adjustment for the Finnish 42%
medication refund policy. Across all sensitivity analyses, MPH-
OROS showed extended dominance over MPH-IR t.i.d. when
compared to a Do Nothing scenario. CONCLUSIONS: By
current standards, ICERs for MPH-OROS appear to fall well
within the limits considered acceptable, especially considering
the limited scope of the analysis (patient symptom improvement
only, without taking into account long-term sequelae or impact
on caregivers).
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OBJECTIVES: Coexisting mental health disorders are common
in patients with ADHD and may increase utilization of health
care services and therefore expenditures. The present study was
designed to address the impact of comorbidities on the direct
medical costs incurred by statutory health insurance (SHI) for
patients with and without ADHD. METHODS: For a retrospec-
tive matched cohort study, concomitant diagnoses and health
care resource utilization data for patients age 7 to 19 years with
a diagnosis of ADHD (F90.0 and/or F90.1) and for a randomly
selected control group (matched 1:1 by age and gender) were
extracted from the Nordbaden claims database (for year 2003),
and were combined with SHI prescription data. Complete
datasets were available for 2171 children age 7–12 years and 768
adolescents age 13–19 years with a diagnosis of ADHD, plus the
same number of control persons. For costing, resource use was
valued applying SHI acquisition costs. Patient subgroups were
deﬁned by the (additional) presence of the most prevalent comor-
bidities, i.e., conduct and personality disorders, mood and affec-
tive disorders, speciﬁc development disorders, and adjustment
disorder. RESULTS: Average costs per patient with ADHD were
€622/€661 (children/adolescents) compared to €245/€250 for
controls. ADHD with coexisting conditions caused the following
direct medical expenditures: in the additional presence of
conduct and personality disorder, €703/€769; mood and affective
disorders, €714/€761; speciﬁc development disorders, €630/
€766; adjustment disorder, €829/€963. Average costs for patients
with these disorders but without ADHD were also increased, and
will be reported in detail. CONCLUSIONS: The present data are
limited since they do neither include costs of inpatient treatment
nor cost of ergotherapeutic interventions, which will have to be
addressed in future studies. They provide nevertheless, for the
ﬁrst time, insight into the impact of coexisting conditions on the
ﬁnancial burden for the SHI associated with a diagnosis of
ADHD.
PODIUM SESSION I: QUALITY OF LIFE/PREFERENCE-
BASED MEASURES I: ISSUES WITH INSTRUMENTS
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AGGREGATION OF DATA FROM MULTIPLE LANGUAGES AND
CULTURES: REPORT FROMTHE ISPORTASK FORCE ON
TRANSLATION AND LINGUISTICVALIDATION
Wild D1, Martin M2, Hareendran A3, von Maltzahn R1
1Oxford Outcomes Ltd, Oxford, UK, 2Health Research Associates Inc,
Seattle,WA, USA, 3Pﬁzer, Ltd, Sandwich, UK
OBJECTIVE: The increasing inclusion of Patient Reported
Outcome (PRO) measures in large multi-country trials has intro-
duced many new methodological challenges. PROs are often
developed in English and translated into the various languages
needed to support these global trials. Data is often pooled and
there are concerns about the process, but currently no established
criteria, to assure the appropriateness of the aggregation of data
derived from multiple languages and cultures. METHODS: A
literature review was conducted in order to investigate what
methods have been used to assess measurement equivalence
across translated PROs. Discussions were held between members
of the task force and comments were sought from the ISPOR
membership. RESULTS: A diverse range of methods have been
employed to assess measurement equivalence across translated
PROs. These include: classical test theory, factor analysis, struc-
tural equation modelling (SEM), and Differential Item Function-
ing (DIF). Basic measurement characteristics such as means,
standard deviations etc have been evaluated when the samples
are large enough, or basic measurement properties (distribution,
internal consistency etc) have been veriﬁed in a at least a few
languages. If measurement equivalence is lacking it is suggested
that qualitative research, analysis of existing trial datasets,
and/or consultation with in-country health professionals could
be carried out to investigate possible reasons for the lack of
equivalence. CONCLUSION: While data pooling across
languages/cultures is common practice, there is no clear recom-
mendation about methods or the level of measurement equiva-
lence required to determine whether pooling is appropriate or
not. There is a need for practical steps to be taken in order to
investigate and resolve lack of measurement equivalence and a
great need for further research in this area.
QL2
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OBJECTIVES: To help clinicians determine the presence of sui-
cidality, the C-SSRS was developed in US English and contains
suggested probes to assess suicidal ideation and behaviour, their
severity, and lethality of suicidal attempts. Prior to use in an
international study to investigate suicidality, the clinician rated
C-SSRS had to be translated into 45 languages for 33 countries. A
rigorous methodology was required to ensure conceptual equiva-
lence and cultural relevance across languages. METHODS: The
process was conducted by specialists in each target country,
following a standardized methodology: 1) two forward transla-
tions by native target language speakers; 2) comparison and
reconciliation of the translations; 3) back translation by a native
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English speaker; 4) comparison of original and back translation;
and 5) review by a clinician. RESULTS: Cultural and linguistic
challenges emerged during the process. On the cultural level, the
differences in the approach to suicide and its methods based on
differences in tradition and availability of means required ﬁnding
suitable alternatives in the target languages.On the linguistic level,
it was important to differentiate between medical and psychiatric
hospitalisation after a suicide attempt and appropriate solutions
across languages had to be found. The process revealed an area of
ambiguity in the original rating instructions which had to be
clariﬁed in the translations. Examples of these and other chal-
lenges and their solutions will be discussed in the presentation.
CONCLUSIONS: The 45 language versions, of the C-SSRS (a
total of over 90 translations now exist), were established accord-
ing to a rigorous methodology to ensure conceptual equivalence
and cultural relevance across languages. The translations may
now be used in international studies to assess suicidal ideation and
behaviour and facilitate the comparison and pooling of data. The
analysis of the psychometric results will be necessary to see if and
how suicidal ideation and behaviour compare across countries
and cultures.
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INTRODUCTION: The EMEA reﬂection paper on HRQL
speciﬁes that the claim in the Summary of Product Characteris-
tics (SmPC) with respect to HRQL will always be considered
depending on the strength of the evidence, which should be
based on 6 criteria, amongst these are the justiﬁcation of the
choice of the HRQL instrument(s), and the evidence of valida-
tion (including for translation). To meet these requirements,
users should have access to reliable and updated information. To
determine if these can be met, it is necessary to review how users
access information about HRQL instruments. OBJECTIVES: 1)
To investigate how developers organize the release of informa-
tion about their instrument; 2) to comment on the pros and cons
for each identiﬁed dissemination strategy; 3) To make recom-
mendations for instrument developers to facilitate users’ access
to information. METHODS: we conducted a review of the
2,850 information requests addressed to our Information
Resources Centre in 2007. The requests were categorized
according to the type of information needed: 1) information
about the original instrument; 2) conditions of access/use of
instruments/translations; 3) validity of instruments/translations;
4) translation certiﬁcation; 5) intellectual property. To address
these, we made 900 contacts with developers, translators, pub-
lishers and other licensing authorities. RESULTS: Out of the
dissemination strategies identiﬁed and reviewed, ﬁve trends
emerged between two extremes: 1) uncontrolled, de-centralized,
free access to non-updated information without developer’s
input; 2) controlled, copyright-protected, centralized, fee-paying
access to reliable and updated information with developer’s
input. Advantages and disadvantages of strategies will be dis-
cussed. Examples demonstrate that the controlled strategy is
more compliant with the EMEA evidence requirements. CON-
CLUSION: Findings indicate that how a user can comply or not
with the EMEA requirements is directly related to how develop-
ers organize the release of information about their questionnaire
and translations. Promoting a controlled, centralized system
with developers’ input may facilitate access to reliable and
updated information.
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OBJECTIVES: To determine if the European Organization for
Research and Treatment of Cancer Quality of Life Question-
naire (EORTC QLQ-C30) can satisfactorily predict EQ-5D,
SF-6D and 15D utilities. The QLQ-C30 measures health-related
quality of life (HRQOL) using a global scale, ﬁve functional
scales and eight symptom scales/items and like most HRQOL
instruments provides a proﬁle of scores instead of an overall
preference-based index, precluding its use in cost-utility studies.
METHODS: A stratiﬁed sample (N = 48) of gastrointestinal
cancer patients on chemotherapy was interviewed. The survey
contained the QLQ-C30, the SF-36, two multi-attribute utility
instruments (EQ-5D and 15D) and socio-demographic and
disease-related questions. Validity of QLQ-C30 scales was
assessed by testing a priori hypotheses that they would be mod-
erately or strongly correlated with SF-36 scales measuring
similar HRQOL dimensions and that younger subjects and those
not reporting comorbid conditions would have better scores.
Linear regression analyses identiﬁed the extent to which QLQ-
C30 scales could predict EQ-5D, SF-6D and 15D utilities.
RESULTS: Pearson’s correlations between similar QLQ-C30
and SF-36 scales ranged from 0.69 to 0.89 (P < 0.001). Subjects
with coronary heart disease had worse scores on all QLQ-C30
functional scales (T-test, P < 0.05 for four scales), as did older
subjects as well (ANOVA, P < 0.05 for ﬁve scales). QLQ-C30
global, functional and symptom scales were signiﬁcant predic-
tors of utility scores elicited from standard instruments. Speciﬁ-
cally, three scales were signiﬁcant (P < 0.05) predictors of
EQ-5D utilities, six scales (P < 0.05) of SF-6D utilities and four
scales (P < 0.001) of 15D utilities and explained large portions
of variance (adjusted R2 was 0.610, 0.833 and 0.912 respec-
tively). Robustness of results was tested and conﬁrmed in patient
subgroups with differing HRQOL. CONCLUSIONS: Prelimi-
nary evidence has been provided supporting the appropriateness
mainly of the 15D and SF-6D instruments in cancer-speciﬁc
cost-utility studies, although further studies involving larger and
more diverse patient samples are encouraged.
PODIUM SESSION II: CARDIOVASCULAR
DISEASE EVALUATIONS
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OBJECTIVES: Therapies may reduce short-term rates of non-
fatal myocardial infarction (MI) while having no detectable effect
on in-trial mortality. We sought to estimate the clinical beneﬁt of
preventing a non-fatal MI in terms of its effects upon long-term
rates of death and MI. METHODS: We analyzed 14,890 patients
with signiﬁcant coronary artery disease (CAD) undergoing diag-
nostic catheterization (cath) at Duke Medical Center between
1999 and 2006, with follow-up through June 2007. Patients
were classiﬁed as having a non-fatal MI within three months of
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